Anti-tumor actions of major component 3′-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation

Cancer Letters

Volumn 265, Issue 1, 2008, Pages 84-97

  Kimura, Yoshiyuki ^a   Sumiyoshi, Maho ^a   Baba, Kimiye ^b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

3 O Acetylhamaudol; Anti angiogenesis; Anti metastasis; Anti tumor; VEGFR 2 phosphorylation

Indexed keywords

3' O ACETYLHAMAUDOL; ANGIOGENIC FACTOR; ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; CEDIRANIB; CHALCONE DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGELICA JAPONICA; ANGELICA KEISKEI; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; IMMUNOMODULATION; INTESTINE EPITHELIUM; LYMPHOCYTE ACTIVATION; MALE; MEDICINAL PLANT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMALL INTESTINE; SPLEEN;

ANGELICA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELLS, CULTURED; CHROMONES; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR SPACE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTESTINAL MUCOSA; INTESTINE, SMALL; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PLANT ROOTS; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ANGELICA JAPONICA; ANGELICA KEISKEI; MUS;

EID: 43449130378     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.009     Document Type: Article

References (46)

1. Kimura Y., and Baba K. Antitumor and antimetastatic activities of Angelica keiskei roots. Part 1: Isolation of an active substance, xanthoangelol. Int. J. Cancer 106 (2003) 429-437
2. Kimura Y., Taniguchi M., and Baba K. Antitumor and antimetastatic activities of 4-hydroxyderricin isolated from Angelica keiskei roots. Planta Med. 70 (2004) 211-219
3. Folkman J. Angiogenesis. Annu. Rev. Med. 57 (2006) 1-18
4. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp. Cell Res. 312 (2006) 594-607
5. Folkman J. Is angiogenesis an organizing principle in biology and medicine?. J. Pediatr. Surg. 42 (2006) 1-11
6. Davis-Smyth T., Chen H., Park J., Presta L.G., and Ferrara N. The second immunoglobulin-like domain of the VEFG tyrosine kinase receptor initiate a signal transduction cascade. EMBO J. 15 (1996) 4919-4927
7. Bernatchez P.N., Soker S., and Sirois M.G. Vascular endothelial growth effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J. Biol. Chem. 274 (1999) 31047-31054
8. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 5 (2000) 3-10
9. Ferrara N., Gerber H.P., and Lecouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
10. Meyer M., Clauss M., Lepple-Wienhues A., Waltenberger J., Augustin H.G., Ziche M., Lanz C., Büttner M., Rziha H.-J., and Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18 (1999) 363-374
11. Karkkainen M.J., and Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19 (2000) 5598-5605
12. Hock H., Dorsch M., Kunzenforf Y., Quin Z., Diamanstein T., and Lanskenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc. Natl. Acad. Sci. USA 90 (1993) 2774-2778
13. + T cell in the antitumor immune response. J. Exp. Med. 188 (1998) 2357-2368
14. + T cells mediated tumor rejection. J. Immunol. 168 (2002) 1-4
15. Colomno H.P., and Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?. Immunol. Today 15 (1994) 48-51
16. Ma H.-L., Whiters M.J., Konz R.F., Senices M., Young D.A., Grusby M.J., Collins M., and Dunussi-Joannopoulos K. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perfolin but are independent of IFN-γ. J. Immunol. 171 (2003) 608-615
17. Iigo M., Kuhara T., Ushida Y., Sekine K., Moore M.A., and Tsuda H. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin. Exp. Metastasis 17 (1999) 35-40
18. Wang W.-P., Iigo M., Sato J., Seike K., Adachi I., and Tsuda H. Activation of intestinal mucosal immunity in tumor bearing mice by lactoferrin. Jpn. J. Cancer Res. 91 (2000) 1022-1027
19. Maeda Y., and Kimura Y. Antitumor effects of various low-molecular-weight chitosans are due to increased natural killer activity of intestinal intraepithelial lymphocytes in sarcoma 180-bearing mice. J. Nutr. 134 (2004) 945-950
20. Baba K., Hata K., Kimura Y., Matsuyama Y., and Kozawa M. Chemical studies of Angelica japonica A. Gary. I. On the constituents of the ethyl acetate extract of the root. Chem. Pharm. Bull. 29 (1981) 2565-2570
21. Kimura Y., and Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J. Nutr. 131 (2001) 1844-1849
22. Kimura Y., and Sumiyoshi M. Antitumor and antimetastatic actions of eicosapentaenoic acid ethylester and its by-products formed during accelerated stability testing. Cancer Sci. 96 (2005) 441-450
23. Kimura Y., Kido T., Takaku T., Sumiyoshi M., and Baba K. Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions. Cancer Sci. 95 (2004) 758-764
24. Albuquerque M.L.C., Waters C.M., Salvia U., Schnaper H.W., and Flozak A. Shear stress enhances human endothelial cell wound closure in vitro. Am. J. Physiol. Heart. Circ. Physiol. 279 (2000) H293-H302
25. Kimura Y., and Okuda H. Effects of naturally occurring stilbene glucosides from medicinal plants and wine, on tumor growth and lung metastasis in Lewis lung carcinoma-bearing mice. J. Pharm. Pharmacol. 12 (2000) 1287-1295
26. Kimura Y. Carp oil or oleic acid, but not linoleic acid or linolenic acid, inhibits tumor growth and metastasis in Lewis lung carcinoma-bearing mice. J. Nutr. 132 (2002) 2069-2075
27. 2 tension. Proc. Natl. Acad. Sci. 92 (1995) 5510-5514
28. Faquin W.C., Schneider J.J., and Goldberg M.A. Effects of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79 (1992) 1987-1994
29. Wagner R.H., and Gassmann M. Oxygene(es) and the hypoxia-inducible factor-1. J. Biol. Chem. 378 (1997) 609-616
30. Hellwig-Bügel T., Rutkowski K., Metzen E., Fandrey J., and Jelkmann W. Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1. Blood 94 (1999) 1561-1567
31. Thronton R.C., Land D., Borghaei R.C., Pease E.A., Caro J., and Mochan E. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synoviol fibroblasts. Biochem. J. 350 (2000) 307-312
32. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
33. Klagsbrun M., and D'Amore P.A. Regulators of angiogenesis. Annu. Rev. Physiol. 53 (1991) 217-239
34. Folkman H., and Shing Y. Angiogenesis. J. Biol. Chem. 267 (1992) 10931-10934
35. Leung D.W., Cachianes G., Kuang W.J., Goefel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
36. Pross H.F., and Lotzova E. Role of natural killer cells in cancer. Nat. Immun. 12 (1993) 279-292
37. Whiteside T.L., and Herberman R.B. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol 7 (1995) 704-710
38. Lode H.N., Xiang R., Dreier T., Varki N.M., Gillies S.D., and Reisfedl R.A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91 (1998) 1706-1715
39. Brunda M., Luistro L., Warrier R.R., Wright R.B., Hunnard B.R., Murphy M., Wolf S.F., and Gately M.K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178 (1993) 1223-1230
40. Trinchieri G. Proinflammatory and immunoregulatory function of interleukin-2. Int. Rev. Immunol. 16 (1998) 365-396
41. Markovic S.N., and Murasko D.M. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma. Cancer Res. 51 (1991) 1124-1128
42. Lasek W., Feleszko W., Golab J., Stoklosa T., Marczak M., Dabrowska A., Malejczyk M., and Jakobisiak M. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice. Cancer Immunol. Immunother 45 (1997) 100-108
43. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., Smith N.R., James N.H., Dukes M., Vurwen J.O., Chester R., Jackson J.A., Voffey S.J., Kilburn L.L., Barnett S., Richmond G.HP., Wafsworth P.F., Walker M., Bigley A.L., Taylor S.T., Cooper L., Beck S., Jürgensmeier J.M., and Ogilivie D.J. AZD2171: highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65 (2005) 4389-4400
44. Strawn L.M., McMahon G., App H., Schreck R., Kuchler W.R., Longhi M.P., Hui H.T.H., Tang C., Levitzki A., Gazit A., Chen I., Keri G., Orfi L., Risau W., Flamme I., Ullrich A., Hirthe K.P., and Shawver L.K. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56 (1996) 3540-3545
45. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., and Tang C. Synthesis and biological evaluations of 3-substituted indoline-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectively toward particular receptor tyrosine kinases. J. Med. Chem. 41 (1998) 2588-2603
46. Sun L., Tan N., Liang C., Tang F., Rice A., Schreck R., Waltz K., Shawver L.K., McMahon G., and Tang C. Design, synthesis and evaluation of substituted 3-[(3-or 4-carboxyethylpyrrol-2yo)methylidenyl]indoline-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem. 42 (1999) 5120-5130